Literature DB >> 23010459

Successful management of congenital chylous ascites with early octreotide and total parenteral nutrition in a newborn.

Claudio Olivieri1, Lorenzo Nanni, Lucia Masini, Claudio Pintus.   

Abstract

Congenital chylous ascites (CCA) is a rare disease that results from maldevelopment of the intra-abdominal lymphatic system. Few cases have been described and no gold standard treatment has been defined so far. Octreotide, a somatostatin analogue, has been used for the treatment of CCA, but always after a failed conservative approach with fasting, total parenteral nutrition (TPN) or medium chain triglyceride (MCT) feeds. We report the case of a newborn with CCA treated by fasting, TPN and octreotide for a period of 15 days until the abdominal distension was successfully reduced at which point treatment was switched to an MCT formula. On day 25 the patient was breastfed and was discharged on day 33. No recurrence of chylous ascites was noted. Our experience highlights the successful treatment with TPN and octreotide as the first step for the conservative approach of CCA in a newborn, reducing the length of treatment and hospitalisation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010459      PMCID: PMC4543147          DOI: 10.1136/bcr-2012-006196

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Chylous ascites: a collective review.

Authors:  O O Aalami; D B Allen; C H Organ
Journal:  Surgery       Date:  2000-11       Impact factor: 3.982

2.  Refractory congenital chylous ascites.

Authors:  Antônio Aldo Melo-Filho; Ivana Jesus Nogueira Souza; Christiane Araújo Chaves Leite; Robério Dias Leite; João Henrique Freitas Colares; Júlio Marcus Sousa Correia
Journal:  Indian J Pediatr       Date:  2010-09-07       Impact factor: 1.967

3.  Congenital chylous ascites: report of four cases and review of the literature.

Authors:  M Machmouchi; A Amin; I Lanjaoui; A Jacobs; C Hatoum; D Al Zahrani
Journal:  Ann Saudi Med       Date:  2000 Sep-Nov       Impact factor: 1.526

4.  Octreotide in congenital chylous ascites an avoid requirement of total parenteral nutrition.

Authors:  Rakesh Mishra; Sanjeev Kumar
Journal:  Indian J Gastroenterol       Date:  2007 Nov-Dec

5.  Successful treatment of congenital chylous ascites with a somatostatin analogue.

Authors:  M G Caty; M L Hilfiker; R G Azizkhan; P L Glick
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

Review 6.  The diagnosis and management of postoperative chylous ascites.

Authors:  Ilan Leibovitch; Yoram Mor; Jacob Golomb; Jacob Ramon
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

Review 7.  Therapeutic management of neonatal chylous ascites: report of a case and review of the literature.

Authors:  Belma Saygili Karagol; Aysegul Zenciroglu; Selim Gokce; Ahmet Afsin Kundak; Mehmet Sah Ipek
Journal:  Acta Paediatr       Date:  2010-09       Impact factor: 2.299

8.  Intractable congenital chylous ascites.

Authors:  A B te Pas; K vd Ven; M P M Stokkel; F J Walther
Journal:  Acta Paediatr       Date:  2004-10       Impact factor: 2.299

9.  Successful management of congenital chylous ascites in a premature infant using somatostatin analogue.

Authors:  Yuefang Huang; Siqi Zhuang; Yijuan Li; Meina Liu; Huiqing Chen; Minlian Du
Journal:  Indian J Pediatr       Date:  2010-10-16       Impact factor: 1.967

10.  The management of chylous ascites in children.

Authors:  D W Man; L Spitz
Journal:  J Pediatr Surg       Date:  1985-02       Impact factor: 2.545

  10 in total
  5 in total

1.  Japanese clinical practice guidelines for vascular anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  Jpn J Radiol       Date:  2020-04       Impact factor: 2.374

2.  Japanese Clinical Practice Guidelines for Vascular Anomalies 2017.

Authors:  Hidefumi Mimura; Sadanori Akita; Akihiro Fujino; Masatoshi Jinnin; Mine Ozaki; Keigo Osuga; Hiroki Nakaoka; Eiichi Morii; Akira Kuramochi; Yoko Aoki; Yasunori Arai; Noriko Aramaki; Masanori Inoue; Yuki Iwashina; Tadashi Iwanaka; Shigeru Ueno; Akihiro Umezawa; Michio Ozeki; Junko Ochi; Yoshiaki Kinoshita; Masakazu Kurita; Shien Seike; Nobuyuki Takakura; Masataka Takahashi; Takao Tachibana; Kumiko Chuman; Shuji Nagata; Mitsunaga Narushima; Yasunari Niimi; Shunsuke Nosaka; Taiki Nozaki; Kazuki Hashimoto; Ayato Hayashi; Satoshi Hirakawa; Atsuko Fujikawa; Yumiko Hori; Kentaro Matsuoka; Hideki Mori; Yuki Yamamoto; Shunsuke Yuzuriha; Naoaki Rikihisa; Shoji Watanabe; Shinichi Watanabe; Tatsuo Kuroda; Shunsuke Sugawara; Kosuke Ishikawa; Satoru Sasaki
Journal:  J Dermatol       Date:  2020-03-22       Impact factor: 4.005

3.  Congenital Chylous Ascites and Ehlers-Danlos Syndrome Type VI.

Authors:  Anna K Ermarth; John Pohl; Brittany Esty; Jessica K Sempler; John C Carey; Molly A O'Gorman
Journal:  ACG Case Rep J       Date:  2016-12-21

4.  Chylous ascites following repair of total anomalous pulmonary venous connection coexisting with a persistent left superior vena cava in a neonate: a case report.

Authors:  Wen Zeng; Yue Hu; Jun Feng; Xiaoli Luo
Journal:  Transl Pediatr       Date:  2021-01

5.  A female infant with phacomatosis pigmentovascularis and congenital chylous ascites: A case report.

Authors:  Shuai Xu; Qinming Zhang; Tingting Liu; Ye Zhang; Ning Sun
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.